Viewing Study NCT00645502

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:37 AM
Ignite Modification Date: 2026-03-08 @ 1:07 AM
Study NCT ID: NCT00645502
Status: COMPLETED
Last Update Posted: 2010-04-26
First Post: 2008-03-24
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet.
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Schizophrenia View
None Schizoaffective Disorders View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Schizophrenia View
None Risperidone View
None Orally-disintegrating tablet View
None Bioequivalence View